Antibiotic-Resistant Gonorrhea: What You Need to Know About the Last Treatment Standing

Antibiotic-resistant gonorrhea is one of the most significant infectious disease threats in sexual health today. The CDC has classified it as an urgent public health threat — the highest category of concern. Gonorrhea has developed resistance to every antibiotic class that has ever been the standard treatment: penicillin, tetracycline, fluoroquinolones, and oral cephalosporins. The current treatment — injectable ceftriaxone — is the last reliably effective option widely available, and resistance to it is emerging in several countries.

Quick answer: Current gonorrhea treatment is a single 500mg injection of ceftriaxone. This is the last broadly effective option. Oral antibiotics no longer work for gonorrhea in most cases. A test of cure (repeat test 1–2 weeks after treatment) is recommended for all gonorrhea cases. If your symptoms don't resolve within a few days of treatment, return to your provider immediately. Testing is available in San Francisco, New York City, Houston, Atlanta, and Washington DC.

How Gonorrhea Develops Resistance

Neisseria gonorrhoeae is uniquely effective at acquiring resistance. It can incorporate foreign DNA from the environment and from other bacteria through a process called horizontal gene transfer. This, combined with its high mutation rate and rapid generation time, allows it to evolve resistance quickly when exposed to antibiotics — often within years of a new treatment becoming the standard of care.

Penicillin became standard in the 1940s; resistance emerged by the 1970s. Tetracyclines followed. Fluoroquinolones (ciprofloxacin) replaced them in the 1990s; by the mid-2000s fluoroquinolone-resistant gonorrhea was widespread enough that the CDC removed them from guidelines entirely. Oral cephalosporins were removed from guidelines in 2012. Injectable ceftriaxone is now the sole first-line agent in most national guidelines.

The Current Treatment Protocol

The CDC 2021 guidelines recommend ceftriaxone 500mg intramuscular injection for uncomplicated gonorrhea of the genitals, rectum, and throat — increased from the previous 250mg dose in response to emerging resistance data. For patients weighing over 150kg, the dose is 1g. Doxycycline 100mg twice daily for 7 days is added if chlamydia coinfection has not been excluded.

Azithromycin is no longer added routinely to ceftriaxone treatment (dual therapy) due to widespread azithromycin resistance. If ceftriaxone is unavailable or a patient has a severe penicillin/cephalosporin allergy, gentamicin 240mg IM plus azithromycin 2g orally is an alternative, but this combination has lower efficacy data and is not preferred.

Why Test of Cure Matters

A test of cure — repeat gonorrhea NAAT 1–2 weeks after treatment — is now recommended for all gonorrhea cases, not just pharyngeal gonorrhea. This is a change from previous guidance that reserved test of cure for suspected treatment failure. The reason: with ceftriaxone being the last effective option, identifying treatment failure early is critical. A positive test of cure result after standard treatment needs to be reported to public health authorities, as it may represent a resistant strain requiring alternative management.

Gonorrhea Without Treatment: What Happens

Untreated gonorrhea in women causes cervicitis, PID, fallopian tube scarring, and infertility. In men it causes urethritis, epididymitis, and potential obstructive infertility. Disseminated gonococcal infection (DGI) occurs when gonorrhea spreads to the bloodstream, causing septic arthritis, skin lesions, and, rarely, endocarditis or meningitis. DGI is more common in women and typically presents as joint pain, fever, and scattered skin pustules — it is an emergency requiring IV treatment. Gonorrhea at any site significantly increases HIV acquisition and transmission risk.

Prevention: Why It Matters More Than Ever

With treatment options becoming increasingly limited, prevention carries greater clinical weight than before. Consistent condom use reduces gonorrhea transmission substantially. Regular testing — every 3–6 months for MSM, annually for others with multiple partners — catches infections before they are transmitted to additional partners and before complications develop. Prompt partner notification ensures all recent contacts are tested and treated simultaneously, preventing ping-pong reinfection.

When to Seek Urgent Care

• Symptoms that don't improve within 3–4 days of treatment: possible treatment failure — return to your provider for repeat testing and assessment.

• Fever with joint pain and skin rash after a gonorrhea diagnosis: possible disseminated gonococcal infection — ER evaluation needed, requires IV antibiotics.

• Severe pelvic pain with fever in women: possible PID requiring same-day treatment.

• Testicular pain and swelling: possible epididymitis — same-day evaluation.

Frequently Asked Questions

Can I take oral antibiotics for gonorrhea?

No longer reliably. Oral cephalosporins have been removed from guidelines due to widespread resistance. Oral azithromycin resistance is extensive. The only effective first-line treatment is ceftriaxone by injection. If you are prescribed oral antibiotics for gonorrhea, ask your provider why and whether injectable ceftriaxone is available.

What does a gonorrhea test of cure involve?

The same NAAT test (urine or swab) you had for the original diagnosis, repeated 1–2 weeks after completing treatment. This confirms the infection has cleared. A positive result at this stage needs to be evaluated as possible treatment failure.

Can gonorrhea come back after treatment?

Yes — through reinfection from an untreated partner or a new partner, not because treatment failed. This is why partner notification and simultaneous treatment of all recent contacts is essential. Without this, reinfection rates are high.

Is there a gonorrhea vaccine?

Not yet for humans, though research is ongoing. Interestingly, the meningococcal B vaccine (MenB/Bexsero) has shown some cross-protection against gonorrhea in observational studies — around 30–40% reduction — because Neisseria gonorrhoeae and Neisseria meningitidis are closely related. This is not an established clinical recommendation but is an active area of research.

Related: Understanding Chlamydia · STI Epidemic 2025 · STD Testing for LGBTQ+ · Get tested today →